Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × pertuzumab × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 58 Neoplasms 8 HER2-positive Breast Cancer 8 Neoplasm Metastasis 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Salivary Gland Neoplasms 2 Prostatic Neoplasms 2 Pathologic Complete Response 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Inflammatory Breast Neoplasms 2 Hematologic Neoplasms 2 HER2-positive Early Breast Cancer 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Anatomic Stage II Breast Cancer AJCC v8 2 Urinary Bladder Neoplasms 1 Solid Tumors 1 Solid Cancer 1 Skin Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Recurrence 1 Rectal Neoplasms 1 Patient Preference 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1

Interventions

Nivolumab 6 Ipilimumab 5 Cisplatin 5 atezolizumab 4 Carboplatin 4 Etoposide 3 gallium Ga 68 dotatate 2 dostarlimab 2 Temozolomide 2 Positron Emission Tomography Computed Tomography 2 Paclitaxel 2 Magnetic Resonance Imaging 2 Immunoglobulin G 2 Drug Therapy 2 Disulfides 2 zimberelimab 1 tivozanib 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 niraparib 1 lutetium Lu 177 dotatate 1 iadademstat 1 durvalumab 1 cabozantinib 1 budigalimab 1 berzosertib 1 belinostat 1 Topotecan 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡